NO20055937L - Anvendels av triglyseridoljer inneholdende gamma-linolensyrerester og linolsyrerester for behandlingen av nevrodegenerativ sydkom - Google Patents

Anvendels av triglyseridoljer inneholdende gamma-linolensyrerester og linolsyrerester for behandlingen av nevrodegenerativ sydkom

Info

Publication number
NO20055937L
NO20055937L NO20055937A NO20055937A NO20055937L NO 20055937 L NO20055937 L NO 20055937L NO 20055937 A NO20055937 A NO 20055937A NO 20055937 A NO20055937 A NO 20055937A NO 20055937 L NO20055937 L NO 20055937L
Authority
NO
Norway
Prior art keywords
acid residues
linolenic acid
patient
neurodegenerative
triglyceride
Prior art date
Application number
NO20055937A
Other languages
English (en)
Norwegian (no)
Inventor
Laurence S Harbige
Michael J Leach
Mohammed Sharief
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of NO20055937L publication Critical patent/NO20055937L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/30Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20055937A 2003-05-14 2005-12-14 Anvendels av triglyseridoljer inneholdende gamma-linolensyrerester og linolsyrerester for behandlingen av nevrodegenerativ sydkom NO20055937L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0311081.4A GB0311081D0 (en) 2003-05-14 2003-05-14 Treatment of neurodegenerative conditions
US49733203P 2003-08-25 2003-08-25
PCT/GB2004/002089 WO2004100943A1 (en) 2003-05-14 2004-05-14 Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
NO20055937L true NO20055937L (no) 2005-12-14

Family

ID=9958058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055937A NO20055937L (no) 2003-05-14 2005-12-14 Anvendels av triglyseridoljer inneholdende gamma-linolensyrerester og linolsyrerester for behandlingen av nevrodegenerativ sydkom

Country Status (15)

Country Link
US (2) US7935729B2 (https=)
EP (2) EP1631280A1 (https=)
JP (2) JP2006528233A (https=)
CN (2) CN1901898A (https=)
AU (1) AU2004237936B2 (https=)
CA (1) CA2524036C (https=)
CH (1) CH699430B1 (https=)
DE (1) DE112004000762T5 (https=)
ES (1) ES2294914B2 (https=)
FI (1) FI122130B (https=)
GB (2) GB0311081D0 (https=)
IS (1) IS8083A (https=)
NO (1) NO20055937L (https=)
SE (1) SE531985C2 (https=)
WO (1) WO2004100943A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
GB2442164B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Treatment of neurodegenerative conditions
GB2442161B (en) * 2003-08-18 2008-05-21 Btg Int Ltd Triglycerides
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
HRP20130551T1 (xx) 2007-03-28 2013-07-31 Aker Biomarine As Biouäśinkovite smjese kril ulja
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
US20110086914A1 (en) * 2009-10-13 2011-04-14 Bailes Julian E Methods for Treating Traumatic Brain Injury
US9500382B2 (en) 2010-04-21 2016-11-22 Honeywell International Inc. Automatic calibration of a demand control ventilation system
US8918218B2 (en) 2010-04-21 2014-12-23 Honeywell International Inc. Demand control ventilation system with remote monitoring
US9255720B2 (en) 2010-04-21 2016-02-09 Honeywell International Inc. Demand control ventilation system with commissioning and checkout sequence control
DK2409695T3 (en) 2010-07-05 2018-05-28 Beth Israel Deaconess Medical Ct Inc SN-2-MONOACYLGYLYCEROLS AND LIPID MALABSORPTION
US8719720B2 (en) 2010-09-24 2014-05-06 Honeywell International Inc. Economizer controller plug and play system recognition with automatic user interface population
US20140044827A1 (en) 2012-08-10 2014-02-13 Bodygenex LLC Dietary supplement containing lyophilized dairy and linolenic acid
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US20160166527A1 (en) 2013-08-01 2016-06-16 Loders Croklaan B.V. Glyceride Composition
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10060642B2 (en) 2014-10-22 2018-08-28 Honeywell International Inc. Damper fault detection
US9845963B2 (en) 2014-10-31 2017-12-19 Honeywell International Inc. Economizer having damper modulation
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
WO2016128838A2 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid compositions
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2077371A (en) 1937-04-13 Synthetic drx
US2077731A (en) * 1935-09-24 1937-04-20 Albert J Aaby Chimney scraper
US2617791A (en) * 1949-09-15 1952-11-11 Trojan Powder Co Recovery of valuable products from pentaerythritol mother liquor
US3082228A (en) * 1959-12-18 1963-03-19 Escambia Chem Corp Method for producing monoesters of polyunsaturated fatty acids
US3158541A (en) * 1959-12-18 1964-11-24 Escambia Chem Corp Product for reduction of blood cholesterol concentration
IE32979B1 (en) * 1968-03-07 1974-02-06 Unilever Ltd Spreadable fats
US3558656A (en) * 1968-04-19 1971-01-26 Smith Kline French Lab Glycerol trichloroethyl carbonate and derivatives
US3671563A (en) * 1968-04-19 1972-06-20 Smith Kline French Lab Glycerol 3-(2,2,2-trichloroethyl) carbonate
US3676472A (en) * 1969-07-28 1972-07-11 American Home Prod Certain linoleic and linolenic acid ester fractions of vegetable oils and derivatives thereof
US3748348A (en) * 1970-07-27 1973-07-24 Lever Brothers Ltd Directed-interesterified glyceridic oils having a high linoleic acid content and process for their production
US3671557A (en) * 1970-09-17 1972-06-20 Smith Kline French Lab 1,2-diacylglycerol 3-(2,2,2-trichloroethyl) carbonates
GB1370021A (en) * 1971-03-25 1974-10-09 Unilever Ltd Process for preparing usaturated carboxylic acids
US3855254A (en) 1972-03-31 1974-12-17 Lever Brothers Ltd Interesterification process
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
US3988446A (en) 1974-11-07 1976-10-26 Abbott Laboratories Glycerides with anti-inflammatory properties
US3972907A (en) * 1975-03-24 1976-08-03 G. D. Searle & Co. Anti-hyperlipidemic fatty acids and esters
US4048202A (en) * 1975-04-11 1977-09-13 G. D. Searle & Co. 3-O-Alkanoylglyceric acids
US4181670A (en) * 1978-12-11 1980-01-01 G. D. Searle & Co. Phenyl 5Z,8Z,11Z,14Z-eicosatetraenoate and congeners
ATE24266T1 (de) * 1982-04-16 1987-01-15 Nestle Sa Lipidhaltige zusammensetzung fuer die orale, enterale oder parenterale ernaehrung.
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
US4701468A (en) * 1983-04-15 1987-10-20 Roussel-Uclaf Oxidized triglycerides having therapeutic utility
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
GB8404463D0 (en) * 1984-02-21 1984-03-28 Efamol Ltd Microbiological production of essential fatty acids
US5077312A (en) 1984-07-08 1991-12-31 Oncogen Biologically active lipids binding membrane receptors
GB2178752B (en) * 1985-07-12 1989-10-11 Unilever Plc Substitute milk fat
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5151291A (en) * 1985-12-27 1992-09-29 Nisshin Flour Milling Co., Ltd. Glycerides of eicosapentaenoic acid, processes for preparing the same and oil and fat products containing the same
US5306730A (en) * 1986-02-03 1994-04-26 Kabushiki Kaisha Yakult Honsha Botulinum toxin neutralizer
US5227403A (en) * 1986-10-01 1993-07-13 The Nisshin Oil Mills, Ltd. Fats and oils having superior digestibility and absorptivity
US4867965A (en) * 1986-10-02 1989-09-19 Revlon, Inc. Fatty acid diesters
FR2617161B1 (fr) 1987-06-29 1989-10-27 Azar Robert Nouveaux glycerides d'acide gras insature et leur procede d'obtention
US4832975A (en) * 1987-09-29 1989-05-23 The Procter & Gamble Company Tailored triglycerides having improved autoignition characteristics
US5008126A (en) * 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
GB9026648D0 (en) 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
PH11992043811B1 (en) 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
DE69420124T2 (de) 1993-01-15 2000-03-02 Abbott Laboratories, Abbott Park Strukturierte lipide
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼcアイソザイムの活性化剤
JPH0741421A (ja) 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンb4 (ltb4 )による医学的症状の予防及び改善剤
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5663450A (en) * 1993-08-17 1997-09-02 Cv Therapeutics Macrophage lipid chemoattractant
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
JPH07309773A (ja) 1994-05-16 1995-11-28 Sagami Chem Res Center アセチルコリン放出促進剤
FR2722410B1 (fr) 1994-07-15 1996-10-04 Grinda Jean Robert Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
JP3770628B2 (ja) 1994-08-09 2006-04-26 サントリー株式会社 遅延型アレルギー反応を介する医学的症状の予防及び改善剤
EP0707850A1 (en) 1994-09-21 1996-04-24 Scotia Holdings Plc Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain
EP0711503A3 (en) 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5990163A (en) 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
DE19503993A1 (de) 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
US6410078B1 (en) * 1995-04-28 2002-06-25 Loders-Croklaan B.V. Triglycerides, rich in polyunsaturated fatty acids
KR100458659B1 (ko) 1995-08-07 2005-06-27 산토리 가부시키가이샤 오메가9계불포화지방산을포함하는연골조직의이상에기인하는의학적증상의예방또는개선작용을갖는음식품및이의제조방법
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
US6015798A (en) * 1995-10-10 2000-01-18 Colgate Palmolive Company Method for reducing the damaging effects of radiation therapy on animal skin and mucosa
JP2000508645A (ja) * 1996-04-12 2000-07-11 ペプテック リミテッド ポリ不飽和脂肪酸を使用する免疫病の治療方法
US5753702A (en) * 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
WO1997046220A1 (en) 1996-06-03 1997-12-11 Croda International Plc Vegetable oil compositions
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
EP0914112A1 (en) * 1996-06-29 1999-05-12 The Scottish Agricultural College Improvement of male fertility with antioxidants and/or polyunsaturated fatty acids
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
ATE236627T1 (de) * 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
JP2001516343A (ja) * 1997-02-21 2001-09-25 アボツト・ラボラトリーズ 壊死性全腸炎の発生を減少させるための方法及び組成物
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6432684B1 (en) * 1997-04-11 2002-08-13 Abbott Laboratories Human desaturase gene and uses thereof
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US6051754A (en) * 1997-04-11 2000-04-18 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
FR2765482B1 (fr) 1997-07-07 2000-12-08 Oreal Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
EP0919230A1 (en) 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
CA2326766A1 (en) 1998-04-03 1999-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusale M Synthetic endogenous cannabinoids analogues and uses thereof
US6696584B2 (en) * 1998-05-04 2004-02-24 Natural Asa Isomer enriched conjugated linoleic acid compositions
US7101914B2 (en) * 1998-05-04 2006-09-05 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6214372B1 (en) * 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
CN1219064C (zh) * 1998-08-04 2005-09-14 嘉吉有限公司 植物脂肪酸去饱和酶启动子
KR100325581B1 (ko) * 1998-08-07 2002-08-24 오우택 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물
WO2000009118A1 (en) * 1998-08-13 2000-02-24 The Wistar Institute Methods for reducing atherosclerotic plaques
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE10029562A1 (de) 1999-06-24 2001-03-01 Strathmann Ag & Co Lipophile Brennesselextrakte, Verfahren zu deren Herstellung und ihre Verwendung
DE19930030B4 (de) 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
FR2797584B1 (fr) 1999-08-16 2008-07-25 Stephane Desjonqueres Utilisation de lipides peroxydes dans le traitement ou la prevention des plaies et inflammations des muqueuses de la cavite buccale
JP3779505B2 (ja) 1999-08-24 2006-05-31 花王株式会社 油脂組成物
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
DE60027376T2 (de) 1999-09-30 2007-02-01 Loders Croklaan B.V. Zusammensetzungen, enthaltend Pinolensäure sowie deren Verwendung zur Gesundheitserhaltung
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20010047036A1 (en) 1999-12-17 2001-11-29 Vanderhoof Jon A. Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome
EG22407A (en) * 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
EP1129711B1 (en) 2000-02-24 2004-01-28 Unilever N.V. Pinolenic acid against diabetes
ATE277608T1 (de) 2000-06-23 2004-10-15 Yissum Res Dev Co 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002047176A (ja) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd IgE産生抑制剤
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2815227B1 (fr) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels
NO310176B1 (no) * 2000-11-13 2001-06-05 Wadlund As Sammensetning for hud som inneholder kitosan-konjugert CLA og kitosankonjugert vitamin A eller et <beta>-cyklodekstrin-konjugertvitamin A samt fremgangsmåte for fremstilling og anvendelse avdenne
US6528040B1 (en) * 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
EP1372641A4 (en) * 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
DE60235303D1 (de) * 2001-07-02 2010-03-25 Suntory Holdings Ltd Verfahren zur herstellung von fett mit triglyceridhaltiger hochungesättigter fettsäure
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
AU784852B2 (en) 2001-08-10 2006-07-06 Mars, Incorporated Canine support diet
US20030032674A1 (en) * 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6677470B2 (en) * 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
ITMI20012732A1 (it) 2001-12-20 2003-06-20 Health Pharma S R L Integratore alimentare per neuropatici
AUPS082102A0 (en) * 2002-03-01 2002-03-21 Women's And Children's Hospital Therapeutic properties of oils
NZ535549A (en) * 2002-03-08 2006-02-24 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
US20040048926A1 (en) * 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
US20060094784A1 (en) 2002-05-17 2006-05-04 Masataka Kagawa Tgf-alpha expression inhibitors
US7335481B2 (en) * 2002-07-24 2008-02-26 Christer Owman Methods of identifying compounds that affect a fatty acid cell-surface receptor
EP1569620A4 (en) 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
US7074418B2 (en) * 2002-11-18 2006-07-11 Changaris David G Conjugated fatty acid based emulsion and methods for preparing and using same
WO2004048504A2 (en) 2002-11-26 2004-06-10 George Washington University Method and composition with conjugated linoleic acid esters
US6841573B2 (en) * 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US20040209953A1 (en) * 2002-12-06 2004-10-21 Wai Lee Theresa Siu-Ling Glyceride compositions and methods of making and using same
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (en) 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof

Also Published As

Publication number Publication date
US7935729B2 (en) 2011-05-03
WO2004100943A1 (en) 2004-11-25
EP2311450A1 (en) 2011-04-20
CA2524036A1 (en) 2004-11-25
AU2004237936A1 (en) 2004-11-25
CH699430B1 (de) 2010-03-15
GB2415378B (en) 2006-08-02
US20080090908A1 (en) 2008-04-17
ES2294914B2 (es) 2010-03-16
GB0521395D0 (en) 2005-11-30
CA2524036C (en) 2014-01-28
JP2006528233A (ja) 2006-12-14
ES2294914A1 (es) 2008-04-01
SE0502484L (sv) 2006-01-16
SE531985C2 (sv) 2009-09-22
US20110184063A1 (en) 2011-07-28
CN1901898A (zh) 2007-01-24
GB2415378A (en) 2005-12-28
CN102512411A (zh) 2012-06-27
FI20051280A0 (fi) 2005-12-13
DE112004000762T5 (de) 2006-03-30
IS8083A (is) 2005-10-21
AU2004237936B2 (en) 2011-03-10
EP1631280A1 (en) 2006-03-08
FI122130B (fi) 2011-09-15
FI20051280L (fi) 2006-02-07
GB0311081D0 (en) 2003-06-18
JP2011144195A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
NO20055937L (no) Anvendels av triglyseridoljer inneholdende gamma-linolensyrerester og linolsyrerester for behandlingen av nevrodegenerativ sydkom
Misidou et al. Complex regional pain syndrome: an update
Eldabe et al. Dorsal root ganglion (DRG) stimulation in the treatment of phantom limb pain (PLP)
Tanida et al. Olfactory stimulation with scent of lavender oil affects autonomic neurotransmission and blood pressure in rats
NO20061232L (no) Behandling av nevrodegenerative tilstander
JP6676062B2 (ja) 認知低下を処置するための方法
Al-Waili Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo
NO20073456L (no) Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling
Hardin Cat's claw: an Amazonian vine decreases inflammation in osteoarthritis
Osman et al. Pulsed compared to thermal radiofrequency to the medial calcaneal nerve for management of chronic refractory plantar fasciitis: a prospective comparative study
Mikkelsen et al. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo
Brockow et al. A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis
MA28005A1 (fr) Traitement preoperatoire de la douleur postoperatoire
US8507007B2 (en) Dermatological composition that can be used in particular for the care and prevention of eschars
RU2180591C2 (ru) Средство для лечения сексуальных дисфункций у мужчин
WO2006007675A1 (en) Cholic acid and/or its derivatives for the reduction of localized fat in the human body
EP1054671B1 (en) New use of ropivacaine for pain management
EP1365771A4 (en) METHOD OF TREATING CERTAIN EYE DISEASES
Rounseville Phantom limb pain: the ghost that haunts the amputee
RU2285550C2 (ru) Способ купирования абстинентного синдрома у пациентов с опийной наркоманией
Hua A 10-year follow-up of electric acupuncture for lumbar disc herniation and sciatica
Limanjaya et al. PD21-11 pericyte-derived exosome promotes caverous angiogenesis and neural regeneration and rescues erectile function
RU2309773C1 (ru) Способ эпидуральной анестезии на поясничном уровне позвоночника
Moreira et al. Recurrent priapism in the young patient treated with baclofen
JP5050851B2 (ja) 疼痛治療剤

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application